A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis

Recruiting now · Phase 3

Conditions studied: Hyperphosphatemia Patients on Peritoneal Dialysis

In brief

An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on peritoneal dialysis

Key facts

Study ID

NCT07548853

Run by

Taisho Pharmaceutical Co., Ltd.

People needed

30

Starts

2026-05-13

Expected to finish

2027-05-31

Last updated by the study team

2026-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hyperphosphatemia patients (outpatients) with chronic kidney disease receiving peritoneal dialysis (CAPD or APD) at least 12 weeks prior to Visit 1 (Week -4)
• Patients aged >= 18 years at the time of obtaining informed consent
• Patients who are receiving at least one phosphate binder and whose dosing regimen for all phosphate-lowering agents (phosphate binder and tenapanor hydrochloride) has been unchanged during the last 4 weeks prior to Visit 1 (Week -4).
• Patients with serum phosphorus concentration of >= 3.5 mg/dL and =< 7.0 mg/dL at Visit 1 (Week -4)
• Patients whose serum phosphorus concentration at Visit 2 (Week -2) or Visit 3 (Week -1) or Visit 4 (Week 0) has increased by at least 1.0 mg/dL compared with the value at Visit 1 (Week -4) and is >= 5.5 mg/dL and < 10.0 mg/dL.

You may not qualify if…

• Patients with confirmed serum intact PTH concentration >500 pg/mL from Visit 1 (Week -4) to Visit 4 (Week 0)
• Patients with serum phosphorus concentration >= 10.0 mg/dL from Visit 2 (Week -2) or Visit 3 (Week -1)
• Patients who have undergone previous parathyroid intervention (PTx, PEIT, etc.)

Where it is running

• Taisho Selected Site — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.